Revance Therapeutics Inc (NASDAQ:RVNC)
| 32.20 Delayed Data As of Mar 31 |  +1.07 / +3.44%Today’s Change | 11.27 Today|||52-Week Range 36.61 | +74.43% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $2.7B |
Company Description
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Contact Information
Revance Therapeutics, Inc. 1222 Demonbreun Street Nashville Tennessee 37203 |
Employees
Shareholders
| Mutual fund holders | 50.63% |
| Other institutional | 45.58% |
| Individual stakeholders | 13.43% |
Top Executives
| Mark J. Foley | Chief Executive Officer & Director |
| Dustin S. Sjuts | President |
| Tobin C. Schilke | Chief Financial Officer |
| Azita Nejad | Senior Vice President-Technical Operations |
| Roman G. Rubio | Senior Vice President-Clinical Development |
